Injectable Contraceptives Market: Global Market by Type, Age Group, Duration of Action, End User, and Region Forecast (2023–2029)

Injectable Contraceptives Market size was valued at USD 123.4 Billion in 2022 and the total Injectable Contraceptives Market revenue is expected to grow at a CAGR of 7.2 % from 2023 to 2029, reaching nearly USD 208.6 Billion.
Injectable Contraceptives Market Overview
The contraceptive injection (also called Depo) is an injection of the hormone progestogen. Progestogen is similar to the hormone produced by the ovaries. The contraceptive injection is sold as Depo-Provera or Depo-Ralovera. Injectable contraceptives, also known as birth control shots, are a form of contraception involving receiving hormones to prevent pregnancy. The hormones used in these injections are usually progestin or a combination of progestin and estrogen. Which suppresses ovulation and thickens cervical mucus also helps keep sperm from fertilizing an egg. Injectable contraceptives are a highly effective contraceptives form of birth control that is globally popular. The research has focused on ways to make the injectable contraceptive market such as depot medroxyprogesterone acetate (DMPA) more accessible and improve the side-effect of injectables with very low failure rates compared to other methods.



To know about the Research Methodology :- Request Free Sample Report

Injectable contraceptives have gained popularity among contraceptive users to boost the market growth

The injectable contraceptive method is very effective for birth control. Injectable contraceptives are becoming increasingly more beneficial for women looking for reliable contraception as the accessibility and adverse effect profile of products like Depo Provera improved. These factors drive the market growth during the forecast period. Injectable contraceptives are the second most popular contraceptive method used by 232.8 million women including in several developing countries, after female sterilization, IUD, and oral pills. The worldwide injectable contraceptive market came as a new set of the contraceptive industry with different goals. There is no such birth control method that is 100% effective and safe. The side effects of most methods are not a threat to life, but rattan her inconvenience.

Injectable contraceptives are used to prevent conception along with convenience, privacy, safe and efficient protection to women Injectable contraceptives are associated with low failure rates from 4% with correct and consistent Instead of putting efforts into improving the delivery of existing contraceptive methods, the government has recently chosen to introduce the injectable contraceptive, depot medroxyprogesterone acetate (DMPA) which is known to have adverse effects on women’s health. Injectable Contraceptives Market have gained popularity among contraceptive users in preventing unintended pregnancies. In the reproductive age who need for family planning satisfied by modern contraceptive methods including injectable contraceptives has increased during the forecast period. Rising from 73.6% in 2018 to 76.8 % in 2022. In a few years, its use increased by folds and it is said to provide protection for more than 42 million women globally worldwide.

 



Types of Injectable Contraceptives


Types
Formulations
Hormones
Also Known As


Progestin-only Injectable Contraceptives
Depot-medroxyprogesterone acetate (DMPA)-3 monthly Norethisterone enanthate (NET-EN)-2 monthly
Contains only progestin
The shot,” “the injection,” or “Depo” Marketed as DepoProvera, Megestron, and Petogen


Monthly (Combined) Injectable Contraceptives
Medroxyprogesterone acetate (MPA)/estradiol cypionate and Norethisterone enanthate (NET-EN)/estradiol valerate
Contains both progestin and estrogen
“Combined injectable contraceptives (CICs)” Marketed under many names including Cyclofem, Cyclo-Provera, Feminena, Lunella, Novafem, and Mesigyna



Increasing Demand for Injectable Contraceptives to drive the Injectable Contraceptives Market growth

A number of studies have previously shown that community health workers can provide injectables safely and effectively. The fertility rates showed no sign of change in spite of vast resources committed to decreasing population growth. The total fertility fell from 7.8 to 6.3, the crude birth rate fell from 53/1000 to 46/1000 and the contraceptive prevalence rate from 17% to 27% Injectable contraceptives are very popular contraceptives. Injectable contraceptives are used by more than 10 million women. It is repeatedly endorsed by the WHO and the IPPF and has the lowest failure rate of any method of reversible contraception. Side effects include spotting or amenorrhoea, and rarely, menorrhagia. Injectables are suitable for women who are breastfeeding, as they may even increase the quantity of breast milk. Norplant, an implanted device developed by the Population Council, releases progestogen at a low, steady rate for 5 years.

The unequivocal role of long-acting reversible injectable contraceptives in reducing the rate of unintended pregnancies has been demonstrated in the research. In public health programs, especially in developing countries, international donors, service providers, and philanthropic organizations have major attention and resources in increasing worldwide access. New reversible products with durations between the current 3-month injectable contraceptives and contraceptive implants and intrauterine devices would fill an important gap in the existing contraceptive method mix and would increase choices for women. Injectable Contraceptives Market has been a cornerstone of international family planning programs for decades. Over 40 million women globally use injectable contraceptives to prevent pregnancy. In Africa, more than one-third of modern method contraceptive users rely on injectable contraceptives. The available injectable contraceptives are effective for 1-3 months, and require women to return to their provided monthly or quarterly.
Injectable Contraceptives Market Trends
Injectable contraception is a highly effective form of birth control that is globally popular. The injectable contraceptive market has focused on ways to make injectables such as depot medroxyprogesterone acetate (DMPA) more accessible and improve the side-effect profile of injectables. Injectable contraceptive market Research in the area of injectable contraception has focused on improving access for women through home or self-injection and also task-shifting, and community-based distribution in low-resource areas. Specific to DMPA, studies have focused on lowering the overall dose of medication while maintaining efficacy and improving drug-delivery systems. More research into the association between DMPA and HIV is needed, and also the effects of the administration of DMPA at the time of medication abortion. The report of the injectable contraceptives market focused on lowering the overall dose. Of medication while maintaining efficacy, and improving drug- the delivery system.

Integration of Injectable Contraceptives into Reproductive Health Programs

Injectable contraceptives are increasingly integrated into national and international reproductive health programs. Governments and organizations are recognizing the impact of injectable contraceptives in reducing unwanted pregnancies and maternal mortality. There are concerted efforts to promote and expand the use of injectable contraceptives through awareness campaigns, training healthcare providers, and integrating them into family planning services.

Restraints Impacting the Injectable Contraceptives Market

According to the report, injectable contraceptive forms of birth control double breast cancer risk among young women. The injectable contraceptive market examined younger women, ages 20 to 44, and a link between depo-medroxyprogesterone acetate (DMPA), the main ingredient in the contraceptive sold under the brand Depo-Provera, and breast cancer risk. Depo-Provera, commonly referred to as the birth control shot, is the brand name of the medication depot medroxyprogesterone to acetate, or DMPA for short.

DMPA contains progestin, a synthetic hormone that works like the sex hormone progesterone. The contraceptive shot is usually injected into the buttocks or upper arm once every 3 months, or just under the skin once energy 12 to 14 weeks. The contraceptive contains progestin, the same hormone used in menopausal therapy that has previously been found to increase the risk of breast cancer. The research involved over 1,000 young women diagnosed with breast cancer. About 10 percent of those women reported using DMPA, which study authors say is consistent with nationwide usage patterns.

The research found a relative increase of 20 to 30 percent in breast cancer risk because of injectable contraceptives, they found 265 cases per 100000 users. Injectable contraceptives mention side effects like menstrual changes, irregular bleeding, prolonged/heavy bleeding, amenorrhea (stopping of menstruation), weight gain, headaches, changes in mood or sex drive, and a decrease in bone mineral density. This is expected to restrain the Injectable Contraceptives Market. Moreover, studies from Africa have shown that the risk of HIV infection may increase for women who have been administered injectable contraceptives. Second, the government needs to introspect whether existing methods have been made available to people through informed choice, in a safe manner.
Injectable Contraceptive Market Segment Analysis
Based on By Type, the segments are divided into progestogen-only injectable and combined injectable contraceptives the progestogen-only injectable segment is dominating the market during the forecast period and expecting high revenue growth Of the women who had used between 1 and 19 injections of the cycle discontinued to become pregnant more than 50% of the population get positive results. And pregnancy rate was 82.7 % A progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Synthetic progesterone, or progestogen, is slowly released into the systemic circulation following intramuscular (IM) or subcutaneous (SC) injection.

Based on End Users, the injectable contraceptive market end-user segment is categorized into hospitals, public health, retail pharmacies, online pharmacies, and others. The hospital segment dominate the other segments and held the largest revenue share in 2022. Retail pharmacies are easily accessible to consumers, allowing them to obtain injectable contraceptives with ease. These pharmacies often have trained pharmacists who can provide information and guidance on contraceptive options. Additionally, retail pharmacies cater to a wide range of customers, including those without access to specialized healthcare facilities. The convenience of obtaining injectable contraceptives alongside other healthcare products makes retail pharmacies the dominant segment in the market. The injectable contraceptive owing to worldwide consumption to avoid unplanned pregnancies and STIs. Injectable contraceptives are preferred in hospitals. Injectable contraceptives help to reduce the risk of pregnancy the second most popular segment that held the revenue share is retail pharmacies.

Based on Duration of Action, The market is currently dominating long-acting injectable contraceptives owing to their convenience and efficacy. Depo-Provera and other such long-acting injectable contraceptives offer protection against pregnancy with just a single injection, typically lasting for more than three months. This means that people do not need to frequently take them, which makes them convenient to use, and increases compliance. Those who want a reliable and hassle-free method often choose long-acting options. Although short-acting injectable contraceptives also have their benefits, the longer protection offered by the long-acting segment is preferred by many, which is why it dominates the market.

North America is expected to hold a significant growth of the Injectable Contraceptive Market over the Forecast Period.

The North American contraceptive market is expected to register the highest market share with favorable government programs, a high proportion of unwanted pregnancies, a rise in sexually transmitted illnesses, etc. the U.S government has launched several educational campaigns about family planning and contraception, which boost the market growth during the forecast period. The injectable contraceptive market can be classified based on age group, education, drugs, and devices. Women in the U.S. were provided with health insurance coverage by the government, to help them adopt injectable contraceptives for birth control. The use of injectable contraceptives is increasing worldwide.

In the United States, in united states, 2018-2022, among sexually experienced women aged 15-44, roughly one in nine (11% or 5.8 million) women had ever used emergency contraception had done so once from 4.2 in 2016. Most women who had ever used injectable contraception had done so once (59 %) or twice (24%). According to a Euro Monitor internationals report, India’s market for injectable contraceptives jumped 88% between 2021 between 2018 to 2022, ranking the country third in the world after the US and China. Young adult women aged 20-24 were most likely to have ever used contraception.
Injectable Contraceptives Market Competitive Landscape
A global landscape analysis was conducted, promising sustained injectable contraceptive drug technologies, and research opportunities and partnerships were established with experts in the fields of contraception and drug delivery to identify new approaches in developing a longer-acting injectable contraceptive product. Companies are focusing on improving their product offerings and increasing their distribution networks through partnerships and collaboration to get a larger portion of the market growing start-ups, mergers, and increasing trends of organic and inorganic growth is being witnessed. The key players in the market such as Mayo Clinic, Bayer, Cleveland Clinic, Pfizer, and Teva Pharmaceutical are major key players are using strategies such as acquisition and mergers, partnerships, and investment and divestment, fueling industry growth. Furthermore, large and medium-scale companies are offering highly improved product-type portfolios and customer services. This trend is projected to positively impact the global market during the forecast period
Injectable Contraceptives Market Scope: Inquire before buying



Injectable Contraceptives Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
USD 123.4 Bn


Forecast Period 2023 to 2029 CAGR:
7.2 %
Market Size in 2029:
USD 208.6 Bn


 Segments Covered:
by Types
1.Progestogen-only Injectables
1.1.Depot MedroxyProgesterone Acetate
1.2.Norethisteroneenanthate
1.3.Combined Injectables Contraceptive


by Age Group
1.15–24 years
2.25–34 years
3.35–44 years
4.Above 44 years


by Duration of Action
1.short-acting Injectable Contraceptives
2.Long-acting Injectable Contraceptives


by End User
1.Hospital
2.Gynaecology Clinics
3.Retail Pharmacies
4.Online Pharmacies
5.Public Health Programs
6.Others



Injectable Contraceptives Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan the and Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A)
Injectable Contraceptives Market Key players
1. Mayo Clinic
2. Bayer
3. Cleveland Clinic
4.Pfizer
5.Teva pharmaceutical
6. AMPHASTAR PHARMS INC
7.Fresenius Kabi AG
8.Hikama Pharmaceuticals plc
9. Sandoz International GmbH (Novartis International AG)
10. Sagent Pharmaceuticals, Inc. (Nichi-Iko Pharmaceutical Co. Ltd.)
11.Sanofi S.A.
12. Baxter International Inc.
13.Exporterindia.com
14.Sqnofi
15. Novo Nordisk
16. Cipla Limited
17. Novartis AG
18. Glenmark Pharmaceuticals Limited

Frequently Asked Questions:

1] What is the growth rate of the Global Injectable Contraceptives Market?
Ans. The Global Injectable Contraceptives Market is growing at a significant rate of 7.2 % during the forecast period.

2] Which region is expected to dominate the Global Injectable Contraceptives Market?
Ans. North America is expected to dominate the Injectable Contraceptives Market during the forecast period.

3] What is the expected Global Injectable Contraceptives Market size by 2029?
Ans. The Injectable Contraceptives Market size is expected to reach USD 208.6 Bn by 2029.

4] Which are the top players in the Global Injectable Contraceptives Market?
Ans. Some of the top players operating in the Injectable Contraceptives Market are Mayo Clinic, Bayer, Cleveland Clinic, Pfizer, and Teva Pharmaceutical

5] Which sector is the key driver in the Injectable Contraceptives Market?
Ans. Increasing the demand of injectable contraceptives in the future is the key driver in the Injectable Contraceptives Market.